Skip to main content
. 2022 Jun 9:10.2217/fon-2022-0148. doi: 10.2217/fon-2022-0148

Figure 3. Anti-SARS-CoV-2 S1 IgG antibody levels in non-previously infected patients according to anticancer therapies.

Figure 3.

(A) Differences in antibody titers against S1 protein of SARS-CoV-2 in cancer patients at different time points according to anticancer therapy received and in control subjects; Wilcoxon signed-rank test and Mann–Whitney U test. No subjects had previous COVID-19 infection. (B) Proportion of cancer patients with antibodies against S1 protein of SARS-CoV-2 at different time points according to anticancer therapy received and in control subjects; chi-square test. None had previous COVID-19 infection. Patients with IgG values ≥880 ng/ml (≥44 BAU/ml) were considered to have a high probability of immune protection against SARS-CoV-2.

ChT: Chemotherapy; Controls: Healthy control; ICI: Immune checkpoint inhibitor; TT: Targeted therapy.